FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that on October 19, 2021 PDS Biotech granted nonstatutory stock options to (a) Matthew Hill, PDS Biotech’s Chief Financial Officer to purchase 202,800 shares of PDS Biotech common stock, (b) Siva K.